Immunotherapy in NSCLC: How Much Is Enough?

Details werden geladen...

Immunotherapy in NSCLC: How Much Is Enough?

Immunotherapy has moved from a last-resort option in NSCLC to a fixture at nearly every stage of the disease, but there's a gap between what the trials tested and how it's actually being used.

IMpower030: Atezolizumab Misses Primary Endpoint in NSCLC

WCLC 2026

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

We Might Have Been Wrong About How the Immune System Ages

Advances in Care for Rare Pediatric Lung Diseases

BRCA Mutation Carriers Likely to Have Risk-Reducing Surgery

Registrieren

Immunotherapy in NSCLC: How Much Is Enough?

IMpower030: Atezolizumab Misses Primary Endpoint in NSCLC

WCLC 2026

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

We Might Have Been Wrong About How the Immune System Ages

Advances in Care for Rare Pediatric Lung Diseases

BRCA Mutation Carriers Likely to Have Risk-Reducing Surgery